BioWorld

June 6, 2006

Tysabri Cleared; FDA Gives 'Very Rare' Second Approval

The FDA is allowing Tysabri to return to the market in a limited capacity for multiple sclerosis patients, three months after an advisory committee voted unanimously in favor of doing so. (BioWorld Today) Read More

Genelabs' HCV Program Nets Potential $200M Novartis Deal

Early ASCO Headlines Made By Pharma's Sutent, Tykerb

Cervarix Showing Promise As Cervical Cancer Field Crowds

Myogen Starting Phase III For BP-Lowering Drug Darusentan

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

Woman taking medication for mental illness

Autobahn on the fast track with bipolar thyroid agonist

BioWorld

Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...